Geoffrey Donnan
Overview
Explore the profile of Geoffrey Donnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
3259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCrowe C, Mirabedini A, Pang T, Cowell K, Langenberg F, Williams C, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2025 Mar;
2024:1-5.
PMID: 40038949
This paper presents a Virtual Reality (VR) experience, specifically tailored for product design, ergonomic assessment, and spatial configuration of advanced, compact imaging technologies in emergency vehicles. The study explores the...
2.
Shiomi Y, Miwa K, Jensen M, Inoue M, Yoshimura S, Kamogawa N, et al.
Int J Stroke
. 2025 Feb;
:17474930251322034.
PMID: 39921231
Background: The effects of intravenous alteplase in patients with prior antiplatelet therapy (APT) remain controversial. We aimed to assess the efficacy and safety of imaging-based intravenous alteplase in patients with...
3.
Barker J, Swarup O, Kusuma Y, Churilov L, Donnan G, Davis S, et al.
J Stroke
. 2025 Feb;
27(1):118-121.
PMID: 39916461
No abstract available.
4.
Beharry J, Yogendrakumar V, Barros G, Davis S, Norrving B, Figtree G, et al.
Eur Stroke J
. 2025 Jan;
:23969873241309516.
PMID: 39745075
Introduction: Little is known of the long-term prognosis of patients with acute ischaemic stroke in the absence of standard modifiable stroke risk factors (SMoRFs). In acute coronary syndromes, patients without...
5.
Yogendrakumar V, Campbell B, Campbell B, Churilov L, Garcia-Esperon C, Choi P, et al.
Int J Stroke
. 2024 Dec;
20(3):367-372.
PMID: 39654273
Rationale: The benefit of tenecteplase in the treatment of large vessel occlusion (LVO) patients presenting within 24 h of symptom onset remains unclear. Aim: This study aimed to assess the...
6.
Burns C, Sanders A, Sanders L, Dalli L, Feigin V, Cadilhac D, et al.
Neuroepidemiology
. 2024 Oct;
:1-9.
PMID: 39467531
Background: Cerebrovascular accident (CVA) is an outdated term for describing stroke as it implies stroke is an accident. We conducted an integrative review to examine the use of CVA in...
7.
Gao L, Parsons M, Churilov L, Zhao H, Campbell B, Yan B, et al.
Eur Stroke J
. 2023 May;
8(2):448-455.
PMID: 37231684
Background: Tenecteplase administered to patients with ischaemic stroke in a mobile stroke unit (MSU) has been shown to reduce the perfusion lesion volumes and result in ultra-early recovery. We now...
8.
Lim H, Lui B, Tacey M, Barit D, Patel S, Donnan G, et al.
Thromb Res
. 2023 May;
226:127-135.
PMID: 37150026
Background: Despite cardiovascular diseases and thrombosis being major causes of death in patients with chronic kidney disease (CKD), there remains no effective biomarker to predict thrombotic risk in this population....
9.
Bivard A, Garcia-Esperon C, Churilov L, Spratt N, Russell M, Campbell B, et al.
Int J Stroke
. 2023 Jan;
18(6):751-756.
PMID: 36655938
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasminogen activator, tenecteplase, has been previously shown to increase early biological effectiveness (reperfusion) resulting in early clinical...
10.
Bernhardt J, Churilov L, Dewey H, Donnan G, Ellery F, English C, et al.
Int J Stroke
. 2022 Nov;
18(6):745-750.
PMID: 36398582
Rationale: The evidence base for acute post-stroke rehabilitation is inadequate and global guideline recommendations vary. Aim: To define optimal early mobility intervention regimens for ischemic stroke patients of mild and...